| Jan 9, 2026 | Diagonal Therapeutics | $125.0M Series B | Janus Henderson Investors, Paulina Hill | Atlas Venture, Balyasny Asset Management, Biovision Ventures, BVF Partners, Checkpoint Capital, EcoR1 Capital, Frazier Life Sciences, Lightspeed Venture Partners, Logos Capital, RA Capital Management, RV Invest, Velosity Capital, Viking Global Investors |
| Jan 8, 2026 | Century Therapeutics | $135.0M Other Equity | TCGX | Commodore Capital, JDRF T1D Fund, RA Capital Management, RTW Investments, Venrock |
| Oct 1, 2025 | Hemab | $160.0M Series C | Soffinova Partners | Access Biotechnology, Amzak Health Investors, HealthCap, Avoro Capital Advisors, Invus, Maj Invest, Novo Holdings, RA Capital Management, Rock Springs Capital |
| Oct 1, 2025 | Tubulis | $360.0M Series C | Venrock | 5AM Ventures, Abingworth, Andera Partners, Coparion, EQT Life Sciences, Frazier Healthcare Partners, Hakan Goker, Third Rock Ventures, Versant Ventures, Lorence Kim, Bayern Kapital, Patrick Heron, Fund+, Frank Hensel, LSP, Nextech Invest, OCCIDENT, Seventure Partners, Wellington Management |
| Sep 22, 2025 | Avenzo Therapeutics | $60.0M Series B | OrbiMed, SR One | Foresite Capital, Lilly Asia Ventures, Delos Capital, INCE Capital, Longwood Fund, New Enterprise Associates, Quan Capital, Sands Capital, Sofinnova Ventures, Surveyor Capital, TF Capital |
| Apr 1, 2025 | Attovia Therapeutics | $90.0M Series C | Deep Track Capital | Frazier Healthcare Partners, venBio |
| Apr 1, 2025 | Imbria Pharmaceuticals | $59.0M Series B | Deep Track Capital | Forbion, RA Capital |
| Dec 1, 2024 | Maze Therapeutics | $120.0M Series D | Deep Track Capital, Frazier Life Sciences | ARCH Venture Partners, Frazier Healthcare Partners, Matrix Capital Management Company, SignalFire, Third Rock Ventures |
| Aug 5, 2024 | MBX Biosciences | $63.5M Series C | Deep Track Capital | — |
| May 24, 2024 | Bicycle Therapeutics | $555.0M Other Equity | — | EcoR1 Capital, Fairmount, Forbion, Perceptive Advisors, RA Capital Management |
| Apr 18, 2024 | Korro Bio | $70.0M Other Equity | Deep Track Capital | — |
| Apr 12, 2024 | Eliem Therapeutics | $120.0M Other Equity | — | Boxer Capital, Janus Henderson Investors, Pontifax, RA Capital Management, Samsara BioCapital |
| Apr 10, 2024 | TORL BioTherapeutics | $158.0M Series B | Rebecca Luse | Avidity Partners, Bristol Myers Squibb, Goldman Sachs, Perceptive Advisors, RA Capital Management, UC Investments, Vertex Ventures HC |
| Apr 3, 2024 | Obsidian Therapeutics | $160.5M Series C | Irina Margine, Ph.D. | Atlas Venture, Bristol Myers Squibb, Foresite Capital, Janus Henderson Investors, Logos Capital, Ray Camahort, Paradigm BioCapital, RA Capital Management, RTW Investments, Samsara BioCapital, Surveyor Capital, TCGX, T. Rowe Price Associates, Woodline Partners |
| Mar 26, 2024 | Avenzo Therapeutics | $150.0M Series A | Jakob Dupont, Deep Track Capital, New Enterprise Associates, Sands Capital | Foresite Capital, Judith Li, Carl Gordon, Delos Capital, INCE Capital, Quan Capital, TF Capital |
| Mar 14, 2024 | Tubulis GmbH | $140.1M Series B | Christoph Broja, Kanishka Pothula | Sofia Ioannidou, Bayern Kapital, BioMedPartners, coparion, Evotec, Frazier Life Sciences, Caroline Goddeeris, High-Tech Grunderfonds, OCCIDENT, Seventure Partners |
| Sep 1, 2023 | Mariana Oncology | $180.0M Series B | Forbion, Rebecca Luse | 10X Capital, Access Biotechnology, AirAngels, Atlas Venture, Awesome People Ventures, Backstage Capital, Max Klement, Cambridge Innovation Capital, Darling Ventures, Menlo Ventures, QEY Capital, Silicon Valley Connect, Vitalize Venture Group, Baron Davis, Bobby Goodlatte, Cecilia Stallsmith, Niklas Jansen, Nik Sharma, Scott Belsky, Shane Neman, Siqi Chen, Eli Lilly and Company, Nextech Invest, RA Capital Management, Surveyor Capital |
| Jul 1, 2023 | Septerna | $150.0M Series B | Jake Simson | RA Capital, Samsara BioCapital, Sanofi Ventures, Third Rock Ventures, BVF Partners, Casdin Capital, Catalio Capital Management, Driehaus Capital Management, Goldman Sachs, Invus, Logos Capital, Mirae Asset, Solus Capital, Vertex Ventures HC, Woodline Partners |
| Jun 6, 2023 | Zura Bio | $80.0M Other Equity | Deep Track Capital, Great Point Partners, Suvretta Capital Management | — |
| May 1, 2023 | Carmot Therapeutics | $150.0M Series E | Deep Track Capital | Anthony Philippakis, MPM Capital, RA Capital, The Column Group, Versant Ventures, 5AM Ventures, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, Millennium Management, RA Capital Management, TCGX, Venrock, Willett Advisors |
| May 1, 2023 | OnKure Therapeutics | $54.0M Series C | Surveyor Capital | Acorn Bioventures, Atlas Venture, OrbiMed, BlackRock, Cormorant Asset Management, Perceptive Advisors, Samsara BioCapital |
| Apr 13, 2023 | TORL BioTherapeutics | $158.0M Series B | Amit Sinha | Alexandria Venture Investments, Bristol Myers Squibb, Cowen Healthcare Investments, OCV Partners, Perceptive Xontogeny Venture Fund, UC-RNT Fund, Vertex Ventures HC |
| Feb 1, 2023 | Hemab | $140.0M Series B | Access Biotechnology | Amzak Health Investors, Soffinova Partners, Uya Chuluunbaatar, Marten Steen, Invus, Maj Invest, Jørgen Søberg Petersen, RA Capital Management, Rock Springs Capital |
| Dec 12, 2022 | Apogee Therapeutics | $149.0M Series B | Rebecca Luse, RTW Investments | — |
| Nov 1, 2022 | Lusaris Therapeutics | $60.0M Series A | Andrew Levin | OrbiMed, RA Capital, Boxer Capital, Venrock |
